
Keywords: 23vPPV; 23-valent pneumococcal polysaccharide vaccine; AEFI; adverse events following immunisation; GPRN; General Practice Research Network; GP; General Practitioner; TGA; Therapeutic Goods Administration; Adverse events following immunisation; Pneumococc